[go: up one dir, main page]

ATE193541T1 - Insulinotropes hormon - Google Patents

Insulinotropes hormon

Info

Publication number
ATE193541T1
ATE193541T1 AT89910254T AT89910254T ATE193541T1 AT E193541 T1 ATE193541 T1 AT E193541T1 AT 89910254 T AT89910254 T AT 89910254T AT 89910254 T AT89910254 T AT 89910254T AT E193541 T1 ATE193541 T1 AT E193541T1
Authority
AT
Austria
Prior art keywords
derivatives
insulinotropic hormone
insulinotropic
hormone
glp
Prior art date
Application number
AT89910254T
Other languages
English (en)
Inventor
Joel F Habener
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE193541T1 publication Critical patent/ATE193541T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89910254T 1989-03-20 1989-03-20 Insulinotropes hormon ATE193541T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1989/001121 WO1990011296A1 (en) 1989-03-20 1989-03-20 Insulinotropic hormone
CA000594350A CA1341363C (en) 1989-03-20 1989-03-21 Insulinotropic hormone

Publications (1)

Publication Number Publication Date
ATE193541T1 true ATE193541T1 (de) 2000-06-15

Family

ID=25672535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89910254T ATE193541T1 (de) 1989-03-20 1989-03-20 Insulinotropes hormon

Country Status (6)

Country Link
EP (1) EP0464022B1 (de)
JP (1) JPH04504246A (de)
AT (1) ATE193541T1 (de)
CA (1) CA1341363C (de)
DE (1) DE68929217T2 (de)
WO (1) WO1990011296A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
USRE37302E1 (en) * 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
PL176007B1 (pl) * 1992-06-15 1999-03-31 Scios Inc Nowe pochodne polipeptydu GLP-1
US5616558A (en) * 1992-07-13 1997-04-01 Nisshin Flour Milling Co., Ltd. Medicaments comprising glicentin as active ingredient
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
AU7531094A (en) * 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
EP0658568A1 (de) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU739020B2 (en) 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
EP1062240B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminal veränderte glp-1 abkömmlinge
EP1056775B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
ATE466026T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
AU2610799A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
EP1932535A3 (de) 1998-07-31 2008-10-29 Novo Nordisk A/S Anregung der Beta-Zellbildung
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
ATE509028T1 (de) 1999-03-15 2011-05-15 Novo Nordisk As Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
JP2003525908A (ja) 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 血清脂質の低下
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
ATE445642T1 (de) 2003-08-21 2009-10-15 Novo Nordisk As Trennung von polypeptiden mit einer racemisierten aminosäure
BR122019021416A2 (de) 2003-09-19 2019-12-21
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
CN101171002B (zh) 2005-05-10 2011-07-13 实验室富尼耶公司 肝x受体激动剂的新用途
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
CA2698968A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
BRPI0909397A2 (pt) 2008-03-31 2015-12-15 Glaxo Group Ltd composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão
BRPI0917000A2 (pt) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag proteínas conjugadas com eficácia in vivo prolongada
CN102271775A (zh) 2008-12-08 2011-12-07 诺沃-诺迪斯克有限公司 多肽的逆流提纯
RU2539797C2 (ru) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
KR20110137819A (ko) 2009-03-27 2011-12-23 글락소 그룹 리미티드 약물 융합체 및 컨쥬게이트
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
WO2011039096A1 (en) 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
EP2525833A2 (de) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stabile wachstumshormonverbindungen
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
RS65380B1 (sr) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 kompozicije i njihova upotreba
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK283180A (da) * 1980-07-01 1982-01-02 Novo Industri As Polypeptider og derivater deraf
WO1987006941A1 (en) * 1986-05-05 1987-11-19 The General Hospital Corporation Insulinotropic hormone

Also Published As

Publication number Publication date
WO1990011296A1 (en) 1990-10-04
CA1341363C (en) 2002-05-28
JPH04504246A (ja) 1992-07-30
EP0464022A4 (en) 1992-04-15
EP0464022B1 (de) 2000-05-31
DE68929217D1 (en) 2000-07-06
EP0464022A1 (de) 1992-01-08
DE68929217T2 (de) 2000-11-30

Similar Documents

Publication Publication Date Title
ATE193541T1 (de) Insulinotropes hormon
DE69531889D1 (de) Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
NO954055L (no) Glukogen-liknende insulintropiske peptidanaloger, sammensetninger og fremgangsmåter for anvendelse derav
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
PH23014A (en) Novel insulin derivatives,their use and pharmaceutical agents for the treatment of diabetes mellitus
NO940436L (no) Forlenget avgivelse av peptider
ATE187647T1 (de) Verwendung eines peptids
ATE110083T1 (de) Insulinotropes hormon.
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
DK358384D0 (da) Farmaceutiske midler til bekaempelse af diabetes mellitus
MX9303554A (es) Peptido similar al glucagon y derivados de insulinotropina.
DK283180A (da) Polypeptider og derivater deraf
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
NO891156D0 (no) Superaktive humane insulinanaloger.
ATE98990T1 (de) Menschlicher prourokinase aehnliches polypeptid.
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time